Browse the evidence

Incretin therapies (GLP-1 and dual GLP-1/GIP receptor agonists) produce significant weight loss in adults with obesity by modulating incretin hormone pathways to suppress appetite and reduce caloric intake.

If you have obesity, incretin medications like semaglutide or tirzepatide are highly effective tools for weight loss, working by reducing appetite and slowing digestion. They are taken as weekly (or daily) injections and are most effective when combined with lifestyle changes like a reduced-calorie diet and regular exercise. Be aware that gastrointestinal side effects like nausea are common initially but often improve with slow dose increases. Long-term use is generally required to maintain weight loss, as stopping the medication often leads to weight regain.

Integrating incretin-based pharmacotherapy with structured patient education and behavioral therapy produces significantly greater and more durable weight loss than pharmacotherapy alone.

To get the best results from weight-loss medications, you should combine them with structured lifestyle changes and education. Studies show that patients who receive intensive behavioral support alongside medication lose significantly more weight and keep it off longer than those who rely on medication alone. Look for programs that offer coaching, dietary tracking, and regular check-ins.

Weekly subcutaneous semaglutide (2.4 mg) and tirzepatide (up to 15 mg) produce significantly greater mean weight loss (12-21%) in non-diabetic obese adults compared to daily liraglutide (3 mg, 5-8%) or placebo.

If you have obesity and are not diabetic, newer weekly injections like semaglutide (2.4 mg) or tirzepatide (up to 15 mg) are significantly more effective for weight loss than older daily options like liraglutide. Expect 15-20% body weight loss in clinical trials. Be prepared for gastrointestinal side effects, which usually improve over time. Crucially, stopping the medication typically leads to significant weight regain, suggesting long-term use may be necessary for sustained results.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg and tirzepatide) produce significant weight loss (14.9-20.9%) and improve cardiometabolic risk factors in adults with overweight or obesity, regardless of diabetes status.

If you have overweight or obesity, GLP-1 agonists like semaglutide or tirzepatide are highly effective for weight loss, producing 15-21% body weight reduction in clinical trials. These benefits occur even if you do not have diabetes. Discuss these options with your provider, keeping in mind that cost and access may be barriers, but coverage is expanding for cardiovascular risk reduction.

Semaglutide (2.4 mg weekly) produces significant weight loss (approx. 15%) by acting as a GLP-1 receptor agonist that stimulates satiety centers in the hypothalamus.

Semaglutide is a weekly injectable medication that mimics a gut hormone to signal fullness to the brain. Clinical trials show it can lead to roughly 15% body weight loss when combined with lifestyle changes, significantly outperforming lifestyle changes alone. It requires a prescription and ongoing medical supervision.

Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 25.3%) by acting as a dual GLP-1 and GIP receptor agonist.

Tirzepatide is a weekly injectable medication that mimics two gut hormones (GLP-1 and GIP) to regulate appetite and metabolism. Clinical trials show it can lead to up to 25% body weight loss, significantly outperforming placebo. It requires a prescription and ongoing medical supervision, and discontinuation leads to weight regain.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and substantial weight reduction compared to single-agonist therapies and placebo.

If you have Type 2 Diabetes or Obesity, Tirzepatide is a highly effective once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to lower blood sugar and promote significant weight loss. It is generally considered superior to older single-agonist drugs. To use it safely, you must start with a low dose and gradually increase it to minimize stomach issues, while maintaining a healthy diet and exercise routine. Access may be limited by cost and insurance coverage, so discuss financial assistance or insurance prior authorization with your doctor.

Incretin-based therapies (GLP-1 and dual/triple agonists) produce clinically significant weight loss (15-21%) and improve cardiometabolic, renal, and hepatic outcomes, marking a turning point in obesity management.

Current GLP-1 and dual agonist medications are highly effective for significant weight loss and improving overall health markers like heart and liver function. They represent a major advancement over lifestyle changes alone, though they require long-term commitment and management of potential side effects like nausea.

Dual and triple incretin agonists (e.g., Tirzepatide, Retatrutide) achieve greater weight loss than single GLP-1 agonists by targeting multiple hormonal pathways.

Newer dual and triple hormone agonists offer even greater weight loss potential (up to 21%) than single-agonist GLP-1 drugs. They work by targeting multiple appetite and metabolism pathways simultaneously, making them highly effective for significant obesity.

Once-weekly subcutaneous semaglutide 2.4 mg induces significant weight loss (average 14.9% body weight) in non-diabetic adults with overweight or obesity compared to placebo.

If you have obesity and do not have diabetes, a once-weekly injection of semaglutide (2.4 mg) is a highly effective medical treatment that can lead to an average 15% reduction in body weight over 16 months. This is significantly more effective than placebo and addresses the biological drive to regain weight that often limits lifestyle changes alone.

Retatrutide and dual agonists achieved equivalent mean weight loss of -11.0 kg, surpassing GLP-1RAs which had a mean weight loss of -9.0 kg.

Practitioners can expect retatrutide and dual agonists to provide significant weight loss compared to GLP-1RAs.

Retatrutide excels at achieving ≥ 15% weight loss with an odds ratio of 54.6.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

All obesity management medications (OMMs) showed significantly greater total body weight loss percentage (TBWL%) versus placebo.

Practitioners can consider OMMs as effective options for weight loss in adult patients.

Tirzepatide and semaglutide exceeded 10% total body weight loss and showed the most favorable glycaemic effects.

Tirzepatide and semaglutide may be prioritized for patients needing significant weight loss and glycaemic control.

Time-restricted eating resulted in a mean weight loss of -8.0 kg, while daily calorie restriction resulted in a mean weight loss of -6.3 kg after 12 months.

Both time-restricted eating and daily calorie restriction can lead to weight loss, but the choice may depend on individual preferences.

Participants in the TRE group experienced a significant body weight reduction of -3.56% by month 6 compared to controls.

TRE may be an effective weight loss strategy for adults with type 2 diabetes.

Both TRE and CR groups showed a decrease in HbA1c levels compared to controls.

Both TRE and CR can improve glycemic control in adults with type 2 diabetes.

The low-calorie group lost significantly more weight than the low-fat group, with males losing 11.8 kg and females losing 8.2 kg in the low-calorie group compared to males losing 8.0 kg and females losing 3.9 kg in the low-fat group.

Practitioners may consider caloric restriction more effective for weight loss than a low-fat diet.

There was significantly greater loss of body fat in the low-calorie group compared to the low-fat group.

Caloric restriction may be more effective for reducing body fat than simply lowering fat intake.

Tirzepatide (TZP) caused greater weight loss than placebo (PBO) with a difference of -16.7 kg vs -8.3 kg (p<0.001).

Practitioners can consider TZP as an effective intervention for weight loss in obese patients.

Tirzepatide significantly reduced food intake compared to placebo.

Reducing food intake may enhance the effectiveness of weight loss strategies in obese individuals.

Tirzepatide significantly reduced body weight compared to placebo, with a total pooled mean difference of -11.62 kg (95% confidence interval: -14.24 to -9.01, p < 0.001).

Tirzepatide can be considered an effective treatment option for weight loss in adults with obesity.

In the highest dosage group of 15 mg, 88.1%, 63.3%, and 51.8% of participants achieved weight reductions exceeding 5%, 10%, and 15% respectively.

Higher doses of Tirzepatide are associated with greater proportions of significant weight loss.

At 176 weeks, the mean percent change in body weight among participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, compared with -1.3% among those who received placebo.

Tirzepatide is effective for significant weight loss in individuals with obesity and prediabetes.